Last reviewed · How we verify
tolododekin alfa
At a glance
| Generic name | tolododekin alfa |
|---|---|
| Also known as | ANK-101 |
| Sponsor | Ankyra Therapeutics, Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors (PHASE1)
- A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer (PHASE1)
- A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- tolododekin alfa CI brief — competitive landscape report
- tolododekin alfa updates RSS · CI watch RSS
- Ankyra Therapeutics, Inc portfolio CI